May 13 2011 Pirfenidone Phase 3 Results Published Today in The Lancet

BRISBANE, Calif., May 13, 2011 /PRNewswire/ — InterMune, Inc. (Nasdaq: ITMN) today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a rare and fatal lung disease affecting more than 200,000 patients in the EU and United States combined, with a survival rate of only 20 percent after five years. The results were published in the online version of The Lancet on May 13, 2011, and will be published in a later print version.

Read the entire article at:

http://www.prnewswire.com/news-releases/pirfenidone-phase-3-results-published-today-in-the-lancet-121811908.html 

This entry was posted in Uncategorized. Bookmark the permalink.

One Response to May 13 2011 Pirfenidone Phase 3 Results Published Today in The Lancet

  1. Kasey Mujica says:

    We appreciate you this objective website. That is all I’m able to point out

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>